Highlights of This Issue 2675

SMALL MOLECULE THERAPEUTICS

2677 Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonnie G. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Robert L. Coleman, and Anil K. Sood

2687 Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Kazuharu Kai, Kimie Kondo, Xiaoping Wang, Xuemei Xie, Mary Kathryn Pitner, Monica E. Reyes, Angie M. Torres-Adorno, Hiroko Masuda, Gabriel N. Hortobagyi, Chandra Bartholomeusz, Hideyuki Saya, Debu Tripathy, Subrata Sen, and Naoto T. Ueno

2700 Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Steven R. Whittaker, Glenn S. Cowley, Steve Wagner, Flora Luo, David E. Root, and Levi A. Garraway

2712 Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Matthias Ilmer, Agnès Garnier, Jody Vykoukal, Eckhard Alt, Dietrich von Schweinitz, Roland Kappler, and Michael Berger

2722 Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Dhanya K. Nambiar, Paulraj Rajamani, Gagan Deep, Anil K. Jain, Rajesh Agarwal, and Rana P. Singh

2735 Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

LARGE MOLECULE THERAPEUTICS

2782 High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study
Sylvain Manfredi, Olivier Bouché, Philippe Roggier, Laetitia Dahaf, Marie Anne Loriot, Thomas Aparicio, Pierre Luc Etienne, Jean Pierre Lafargue, Cédric Lécaillle, Jean Louis Legoux, Karine Le Malicot, Emilie Maillard, Thierry Lecomte, Faiza Khemissa, Gilles Breysacher, Pierre Michel, Emmanuel Mitry, and Laurent Bedenne

2789 Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Ronit Mazor, Jingli Zhang, Laiman Xiang, Selamawit Addissie, Prince Awuah, Richard Beers, Raffit Hassan, and Ira Pastan

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo
Heather Venant, Mehrdad Rahmaniyan, E. Ellen Jones, Ping Lu, Michael B. Lilly, Elizabeth Garrett-Mayer, Richard R. Drake, Jacqueline M. Kraveka, Charles D. Smith, and Christina Voelkel-Johnson

Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
Brian Gabrielli, Fawzi Bokhari, Max V. Ranall, Zay Yar Oo, Alexander J. Stevenson, Wei Li Wang, Melanie Murrell, Mushfiq Shaikh, Sora Fallaha, Daniel Clarke, Madison Kelly, Karin Sedelies, Melinda Christensen, Sara McKee, Graham Leggatt, Paul Leo, Dubravka Skalamera, H. Peter Soyer, Thomas J. Gonda, and Nigil A.J. McMillan
Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer–siRNA Chimeras in Human Tumor Xenografts
Xiaohua Ni, Yonggang Zhang, Kenji Zennami, Mark Castanares, Amarnath Mukherjee, Raju R. Raval, Haoming Zhou, Theodore L. DeWeese, and Shawn E. Lupold

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers
Dhara N. Amin, Deepika Ahuja, Paul Yaswen, and Mark M. Moasser

PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Florian Engert, Cornelius Schneider, Lilly Magdalena Weiß, Marie Probst, and Simone Fulda

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor
Yoshito Nakanishi, Hideaki Mizuno, Hitoshi Sase, Toshihiko Fujii, Kiyoko Sakata, Nukinori Akiyama, Yuko Aoki, Masahiro Aoki, and Nobuya Ishii

Pigment Epithelium–Derived Factor Alleviates Tamoxifen-Induced Endometrial Hyperplasia

Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Wei Jiang, Na Liu, Xiao-Zhong Chen, Ying Sun, Bin Li, Xian-Yue Ren, Wei-Feng Qin, Ning Jiang, Ya-Fei Xu, Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yan, Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai, Mu-Sheng Zeng, Tie-Rang Kang, Wei-Hua Jia, Jian-Yong Shao, and Jun Ma

Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients
Tongmeng Yan, Linlin Lu, Cong Xie, Jianwei Chen, Xiaojuan Peng, Lijun Zhu, Ying Wang, Qiang Li, Jian Shi, Fuyuan Zhou, Ming Hu, and Zhongqiu Liu

Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing

Models and Technologies

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer
Sumanta Kumar Pal, Winston Vuong, Wang Zhang, Jiehui Deng, Xueli Liu, Courtney Carmichael, Nora Ruel, Marnesia Pinnamaneni, Przemyslaw Twardowski, Clayton Lau, Hua Yu, Robert A. Figlin, Neeraj Agarwal, and Jeremy O. Jones

Acknowledgment to Reviewers

For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover image shows the structural model of LMB-T20, a highly potent recombinant immunotoxin consisting of an antimesothelin Fv fused to a portion of *Pseudomonas* exotoxin A. The toxin has a deletion of domain II and six point mutations in domain III that delete or greatly suppress the eight T-cell epitopes. For details, see the article by Mazor and colleagues on page 2789.